 Connection
Elizabeth McFarland to Anti-HIV Agents
This is a "connection" page, showing publications Elizabeth McFarland has written about Anti-HIV Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.787 |
|
|
|
-
Abuogi LL, Imran R, Limas A, Moor J, Leonard K, Pierce K, De La Garza AJ, Gallegos S, Duenas J, Littrell Z, Vyas P, Richards M, Straub D, McFarland EJ. Pilot outcomes of a telehealth model for youth PrEP (TelePrEP) among youth at risk for HIV in Colorado. HIV Res Clin Pract. 2025 Dec 31; 26(1):2588009.
Score: 0.560
-
Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.
Score: 0.144
-
Serghides L, Lee J, Jacobson DL, Geffner ME, DiMeglio LA, McFarland EJ, Powis KM, Williams PL, Jao J. Brief Report: Is Gestational Exposure to HIV and Protease Inhibitors Associated With Timing of Pubertal Onset? J Acquir Immune Defic Syndr. 2026 Mar 01; 101(3):302-307.
Score: 0.142
-
Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, Yin DE, Moye J, Spiegel H, Gama L, Gaudinski M, Capparelli EV. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. J Antimicrob Chemother. 2026 Jan 19; 81(2).
Score: 0.141
-
Alba C, Malhotra S, Horsfall S, Barnhart ME, Bekker A, Chapman K, Cunningham CK, Fast PE, Fouda GG, Freedberg KA, Goga A, Ghazaryan LR, Leroy V, Mann C, McCluskey MM, McFarland EJ, Muturi-Kioi V, Permar SR, Shapiro R, Sok D, Stranix-Chibanda L, Weinstein MC, Ciaranello AL, Dugdale CM. Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. PLoS One. 2025; 20(3):e0318940.
Score: 0.133
-
Cunningham CK, McFarland EJ, Muresan P, Capparelli EV, Perlowski C, Johnston B, Bone F, Purdue L, Yin DE, Moye J, Spiegel HML, Majji S, Theron GB, Mujuru HA, Purswani M, Alvarez G, Deville JG, Chambers C, Brown E, Harding PA, Tobin NH, Low K, Gama L. Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1. J Pediatric Infect Dis Soc. 2025 Feb 06; 14(2).
Score: 0.132
-
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 02 01; 92(2):153-161.
Score: 0.115
-
Agwu AL, Warshaw MG, McFarland EJ, Siberry GK, Melvin AJ, Wiznia AA, Fairlie L, Boyd S, Harding P, Spiegel HML, Abrams EJ, Carey VJ. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. PLoS One. 2017; 12(6):e0178075.
Score: 0.078
-
Van Dyke RB, Patel K, Kagan RM, Karalius B, Traite S, Meyer WA, Tassiopoulos KK, Seage GR, Seybolt LM, Burchett S, Hazra R, Lurie RH, Yogev R, Sanders MA, Malee K, Hunter S, Shearer W, Paul M, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Garvie P, Blood J, Burchett S, Karthas N, Kammerer B, Wiznia A, Burey M, Nozyce M, Dieudonne A, Bettica L, Adubato S, Chen J, Bulkley MG, Ivey L, Grant M, Knapp K, Allison K, Wilkins M, Acevedo-Flores M, Rios H, Olivera V, Silio M, Jones M, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Katai A, Dunn J, Paul S, Scott G, Bryan P, Willen E. Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV. Clin Infect Dis. 2016 07 01; 63(1):133-137.
Score: 0.072
-
Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ, Weinberg A. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015; 10(5):e0127062.
Score: 0.067
-
Weinberg A, Harwood JE, McFarland EJ, Pappas J, Davies J, Kinzie K, Barr E, Paul S, Salbenblatt C, Soda E, Vazquez A, Peloquin CA, Levin MJ. Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol. 2009; 2009:621780.
Score: 0.047
-
Weinberg A, Forster-Harwood J, McFarland EJ, Pappas J, Davies JK, Kinzie K, Barr EA, Paul SM, Salbenblatt CR, Soda E, Vazquez A, Levin MJ. Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol. 2009 May; 45(1):39-42.
Score: 0.044
-
Borkowsky W, Yogev R, Muresan P, McFarland E, Frenkel L, Fenton T, Capparelli E, Moye J, Harding P, Ellis N, Heckman B, Kraimer J. Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia. AIDS Res Hum Retroviruses. 2008 Mar; 24(3):401-11.
Score: 0.041
-
Borkowsky W, Yogev R, Muresan P, McFarland E, Frenkel L, Fenton T, Capparelli E, Moye J, Harding P, Ellis N, Heckman B, Kraimer J. Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia. Vaccine. 2008 Jun 06; 26(24):3086-9.
Score: 0.040
-
Starr SE, McFarland EJ, Muresan P, Fenton T, Pitt J, Douglas SD, Deveikis A, Levin MJ, Rathore MH. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children. AIDS. 2003 Oct 17; 17(15):2181-9.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|